WO2009038672A1 - Differential evaporation potentiated disinfectant system - Google Patents
Differential evaporation potentiated disinfectant system Download PDFInfo
- Publication number
- WO2009038672A1 WO2009038672A1 PCT/US2008/010684 US2008010684W WO2009038672A1 WO 2009038672 A1 WO2009038672 A1 WO 2009038672A1 US 2008010684 W US2008010684 W US 2008010684W WO 2009038672 A1 WO2009038672 A1 WO 2009038672A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antimicrobial composition
- amount
- ethylene glycol
- mixture
- percent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
- A01N31/02—Acyclic compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
- A01N33/02—Amines; Quaternary ammonium compounds
- A01N33/08—Amines; Quaternary ammonium compounds containing oxygen or sulfur
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N35/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical
- A01N35/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical containing aliphatically bound aldehyde or keto groups, or thio analogues thereof; Derivatives thereof, e.g. acetals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/02—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N61/00—Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
Definitions
- Alcohols have been extensively utilized in antimicrobial formulations to provide a reduction in populations of viable microorganisms.
- Methanol, ethanol, and N-butanol can each be produced by fermentation and alcohols such as 2-propanol, 2-butanol, 2-pentanol, and so on, can be synthesized from petrochemicals.
- 2-propanol also referred to as isopropanol
- isopropanol has proven more effective than ethanol and methanol in reducing populations of viable microorganisms its use has become widespread in conventional antimicrobial formulations.
- the superior efficacy of isopropanol over methanol and ethanol can be understood, in part, by considering the physical properties as summarized in TABLE 1.
- Negative values of Log P ow represent substances that are more soluble in water, while positive values of Log P ow represent substances that are more soluble in n-octanol.
- the more soluble an antimicrobial material is in n-octanol the more effective the antimicrobial material may be in reducing populations of microorganisms in aqueous solutions. It may be predicted that isopropanol will be a more effective antimicrobial than methanol, ethanol, and acetone based on the Log P ow -
- a first substantial problem with the use of certain alcohols such as methanol and certain ketones such as acetone in or as compositions for the reduction of viable populations of microorganisms can be their relatively high vapor pressures and relatively low flashpoints (FP).
- alcohols and ketones conventionally included in antimicrobial compositions can have vapor pressures and flashpoints which allow ignition even without direct contact with the ignition source and may be regulated as workplace hazards.
- alcohols and ketones conventionally used as or in antimicrobial compositions may have to be shipped as flammable materials under United States Department of Transportation ("DOT") guidelines. Flammable materials can be more costly to transport than materials which are not characterized as flammable under DOT guidelines.
- DOT United States Department of Transportation
- alcohols such as methanol, ethanol and isopropanol and ketones such as acetone
- rate of evaporation can limit the duration of time a viable population of microorganisms is exposed to alcohol or ketone.
- alcohols and ketones can evaporate from the aqueous mixture at a rate which alters the efficacy of the mixture as the concentration of the alcohol or ketone in the mixture reduces over time.
- the instant invention provides a differential evaporation potentiated disinfectant system which provides antimicrobial compositions and methods of using such antimicrobial compositions to potentiate the active components of the composition for the reduction of viable populations of microorganisms in conditioning, cleaning or disinfection of surfaces.
- a broad object of the invention can be to provide a differential evaporation potentiated disinfectant system which includes differential evaporation potentiated antimicrobial compositions and methods of using such differential evaporation potentiated antimicrobial compositions to reduce populations of viable microorganisms.
- infectious means a composition which upon engagement with a population of viable microorganisms provides greater than a 2-logio order reduction (greater than 99% reduction) in the population of viable microorganisms (also referred to herein as an "antimicrobial composition”).
- infectious means a greater than a 2-logio order reduction (greater than 99% reduction) in the population of viable microorganisms.
- viable microorganism means a microorganism capable of reproduction.
- the term "reduction in the population of viable microorganisms” means rendering all or a portion of a population of microorganisms incapable of reproduction whether achieved by killing all or a portion of the population of microorganisms or otherwise incapacitating reproduction of all or a portion of the population of microorganisms.
- the term "differential evaporation potentiated” means a maintenance or increase in the concentration of the antimicrobially active agent(s) included in a composition due to the greater rate of evaporation of the inactive agent(s) included in the composition providing a greater than 2-log ⁇ o order reduction in the population of viable microorganisms, whether upon application or after elapse of a duration of time after application to a viable population of microorganisms.
- a second broad object of the invention can be to provide differential evaporation potentiated antimicrobial compositions which include a mixture of an amount of antimicrobially active agent and an amount of inactive agent each soluble in the other and each establishing an equilibrium between the liquid and vapor phase in accordance with Raoult's law which results in maintenance or an increase in concentration of the antimicrobially active agent over a duration of time.
- differential evaporation potentiated antimicrobial compositions may include an amount of one antimicrobially active agent and an amount of one inactive agent
- the invention is not so limited and the amount of antimicrobial agent can include at least one antimicrobially active agent or a plurality of antimicrobially active agents and the amount of inactive agent can include at least one inactive agent or a plurality of inactive agents the concentrations established in various permutations and combinations which afford a differential evaporation potentiated antimicrobial composition.
- Figure 1 the relationship of the concentrations in liquid phase and vapor phase for one constituent in a mixture which comes to equilibrium in accordance with Raoult's law is represented by line A.
- a third broad object of the invention can be to provide differential evaporation potentiated antimicrobial compositions which include a mixture of an amount of antimicrobially active agent and an amount of inactive agent each soluble in the other and each establishing an equilibrium between the liquid and vapor phase as an azeotrope which results in maintenance or an increase in concentration of the antimicrobially active agent over a duration of time.
- differential evaporation potentiated antimicrobial compositions may include an amount of one antimicrobially active agent and an amount of one inactive agent the invention is not so limited and the amount of antimicrobial agent can include at least one antimicrobially active agent or a plurality of antimicrobially active agents and the amount of inactive agent can include at least one inactive agent or a plurality of inactive agents the concentrations established in various permutations and combinations which as an azeotrope affords a differential evaporation potentiated antimicrobial composition.
- Figure 1 the relationship of the concentrations in liquid phase and vapor phase for one constituent in a mixture which comes to equilibrium from an azeotropic composition is shown by lines B and G.
- Line G represents the equilibrium between the liquid phase and the vapor phase of a binary azeotrope composition including an amount of diacetone alcohol combined with an amount of water as a non-limiting example.
- Point H on Line G represents the azeotrope point, which for the particular example of diacetone alcohol may correspond to a concentration of about 12.7 grams of diacetone alcohol per 100 grams of the combination of diacetone alcohol and water, or about 13.4% diacetone alcohol volume to volume ("v/v").
- a composition established at the azeotrope when evaporated produces a vapor having the same ratio of constituents as the original concentration of the composition as a liquid.
- an initial concentration of diacetone alcohol such as 20% (v/v) (Point J on Line G) in water will cause a shift in the vapor-equilibrium to the right on Line G towards point K and point L, where the differential loss of water to the vapor phase increases.
- an initial concentration of diacetone alcohol such as 10% (v/v) will cause a shift in the vapor- equilibrium to the left on Line G, where the differential loss of diacetone alcohol to the vapor phase increases.
- an initial concentration of diacetone alcohol such as 10% (v/v) in water does not define an antimicrobial composition then evaporation of all or a part of the amount of the diacetone alcohol and water composition fluidically engaged with a population of microorganisms will not increase the concentration of the diacetone alcohol in the composition, but rather over a duration of time the concentration of diacetone alcohol in water will decrease. Accordingly, an initial concentration of 10% (v/v) diacetone alcohol in water may not be potentiated, at standard atmospheric pressure, toward an antimicrobially active composition to reduce the population of viable microorganisms.
- an initial concentration of diacetone alcohol which exceeds the azeotrope point in water does not define an antimicrobial composition but a greater concentration of diacetone alcohol does define an antimicrobial composition
- evaporation of all or a part of the amount of the diacetone alcohol and water composition fluidically engaged with a population of microorganisms can increase the concentration of the diacetone alcohol in the composition over a duration of time and the composition can be potentiated to provide an antimicrobially active composition which can reduce the population of viable microorganisms.
- an initial concentration of diacetone alcohol which exceeds the azeotrope point in water defines an antimicrobial composition
- evaporation of all or a part of the amount of the diacetone and water composition can increase the concentration of the diacetone alcohol in the antimicrobial composition over a duration of time. Accordingly, evaporation of an amount of the antimicrobial composition can occur without loss of antimicrobial activity and the antimicrobial composition can be potentiated to provide an increased level of antimicrobial activity as compared with the initial concentration of the antimicrobial composition.
- a fourth broad object of the invention can be to provide differential evaporation potentiated antimicrobial compositions which are as effective or more effective in reducing populations of microorganisms as compared to conventional antimicrobial compositions.
- Table 2 and Figure 1 it can be understood that a conventional antimicrobial composition of 70% isopropanol in water is well below the azeotrope point of about 87.40% (w/w) or 89.83% (v/v)(see Line B, point C).
- evaporation of all or a part of the amount of a conventional isopropanol in water antimicrobial composition can shift the liquid-vapor equilibrium to the left toward points D, E, and F on Line B and the concentration of isopropanol in the liquid phase can decrease over a duration of time.
- the level of antimicrobial efficacy of such amounts of isopropanol in water upon evaporation can be reduced or lost over the duration of time.
- the inventive differential evaporation potentiated antimicrobial composition of 15% (v/v or w/w) diacetone alcohol is well above the azeotrope point of about 12.70 (w/w) or 13.43% (v/v).
- Line A shows the change in fluid volume of 70% (v/v) isopropanol in water (a conventional antimicrobial composition) caused by evaporation
- line B represents the change in fluid phase concentration of the same 70% (v/v) isopropanol in water occurring during the same fluid volume change.
- complete evaporation of an amount of 70% (v/v) isopropanol in water can occur over about 15 time units.
- Line C represents the change in fluid volume of a 20% (v/v) solution of diacetone alcohol in water caused by evaporation (a particular embodiment of the inventive differential evaporation antimicrobial composition)
- line D represents the change in fluid phase concentration of the same 20% (v/v) diacetone alcohol in water occurring during the same fluid volume change.
- complete evaporation can occur in approximately 75 time units.
- the 20% (v/v) diacetone alcohol in water can be engaged with a population of microorganisms for a greater duration of time than the conventional antimicrobial composition without reapplication of an additional amount because evaporation occurs at a slower rate as shown by Table 3.
- Line B if 10% (v/v) isopropanol provides the minimum effective concentration to provide any reduction in a population of viable microorganisms, then the concentration of isopropanol remaining during the last 2-5 time units may not afford any additional reduction in the population of viable microorganisms because the concentration of isopropanol in the composition has been reduced by evaporation to less than 10% (v/v).
- Line C represents the change in fluid volume of a 20% (v/v) solution of diacetone alcohol in water
- line D represents the change in concentration of diacetone alcohol in water.
- a fifth broad object of the invention can be to provide differential evaporation potentiated antimicrobial compositions which use one or a plurality of antimicrobially active agent(s) that have a Log P between about -1.0 and +1.0 or in a preferred range of about -0.30 and about +1.0.
- Solvents with Log P values above about 1.0 or 1.5 are usually not miscible with water and can be tolerated by certain kinds of microorganism. Substances such as sugars, amino acids, and other highly-water soluble materials, that have large negative Log P values, are also typically tolerated by most microorganisms.
- a sixth broad object of the invention can be to provide a method by which differential evaporation potentiated antimicrobial compositions can be identified from a numerous and varied group of substances.
- Figure 1 is a vapor-liquid phase equilibria diagram which shows the relationship of the concentrations in liquid phase and vapor phase for one constituent..
- Figure 2 is a diagram which shows the relationship between change in liquid phase concentration of a constituent and change in volume of the liquid phase for particular conventional and inventive mixures.
- Figure 3 is a block diagram which provides the steps of a particular method of selecting substances which can be utilized in embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 4 provides chemical structures for particular alpha hydroxyketones which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 5 provides chemical structures for particular beta hydroxyketones which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 6 provides chemical structures for particular ethylene glycol monoethers which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 7 provides chemical structures for particular ethylene glycol diethers which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 8 provides chemical structures for particular ethylene glycol ether esters which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 9 provides chemical structures for particular propylene glycol monoethers which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 10 provides chemical structures for particular propylene glycol diethers which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 11 provides chemical structures for particular propylene glycol ether esters which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 12 provides chemical structures for particular butylene glycol monoethers which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 13 provides chemical structures for particular butylene glycol diethers which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 14 provides chemical structures for particular butylene glycol monoether esters which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 15 provides chemical structures for particular ethylene glycol monoesters which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 16 provides chemical structures for particular ethylene glycol diesters which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 17 provides chemical structures for particular propylene glycol monoesters which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 18 provides chemical structures for particular propylene glycol diesters which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 19 provides chemical structures for particular propylene glycol diesters which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 20 provides chemical structures for particular butylene glycol esters which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 21 provides chemical structures for particular oximes which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 22 provides chemical structures for particular dimethylaminoalcohols which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 23 provides chemical structures for particular pyridines which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- Figure 24 provides chemical structures for particular aliphatic alcohols which can be utilized to produce embodiments of the inventive differential evaporation potentiated disinfection system.
- differential evaporation potentiated antimicrobial compositions and methods of using such differential evaporation potentiated antimicrobial compositions to provide a reduction in populations of viable microorganisms.
- antimicrobial compositions which include an antimicrobially active agent soluble in an inactive agent with the antimicrobially active agent potentiated by differential evaporation providing reduction in a population of viable microorganisms.
- a block diagram provides the steps of a particular method of selecting substances which can be utilized in embodiments of the differential evaporation potentiated disinfection system.
- a determination can be made as to whether an amount of substance (2) is fully miscible or highly soluble in an amount of water (3) at a temperature of between about 5 0 C and about 90°C at about 760mm Hg.
- the miscibility of the amount of substance (2) and the amount of water (3) can be assessed by measuring the partition co-efficient of the amount of the substance solubilized in water under standard conditions of temperature and pressure.
- an amount of substance (2) can be shown to be fully miscible or highly soluble in an amount of water (3) as above described, then in a second selection step (4) a determination can be made as to whether the amount of substance (2) has a melting point at standard atmospheric pressure of below about 0°C and more preferably below about - 20°C.
- the melting point of the amount of substance can be determined by performing a melting point assessment as described in Product Properties Test Guidelines, OPPTS 830.7200, Melting Point/Melting Point Range, United States Environmental Protection Agency (1996), hereby incorporated by reference.
- the boiling point of the amount of substance can be determined by performing a boiling point assessment as described in Product
- the amount of substance (2) has a boiling point at standard atmospheric pressure above about 110°C, them in a fourth selection step (6) a determination can be made as to whether in the absence of water the amount of substance (2) has a flash point at standard atmospheric pressure that is above about 40°C.
- the flash point of the amount of substance can be determined by performing a flash point assessment as described in ASTM D7094-04 Standard Test Method for Flash Point by Modified Continuously Closed Cup (MCCCFP) Tester, ASTM International (2007), hereby incorporated by reference.
- This flashpoint assessment can be made as above-described.
- the Log P of the amount of substance (2) can be assessed by performing the Log P assessment as described by "Slow-stirred Method for Determining the n-Octanol/Water Partition Coefficient (P ow ) for Highly Hydrophobic Chemicals: Performance Evaluation in a Ring Test, Environmental Toxicology and Chemistry, Vol. 22, Issue 5 ( May 2003).
- an seventh selection step (9) a determination can be made as to a range of concentrations of the amount of substance (2) combined with the amount of water (3) in which a differential evaporation potentiated composition (10) can be generated.
- the range can be assessed by generation of vapor-liquid phase equilibria as shown by Figure 1 and as above-described.
- a range of concentrations of the amount of substance (2) generates a differential evaporation potentiated composition (10)
- a particular non- limiting assay to determine whether the a differential evaporation potentiated compositions (10) further afford a differential evaporation potentiated antimicrobial compositions (12) is to provide cultures of microorganisms such as Staphylococcus aureus (ATCC 6538, MRI Sta 21), Pseudomonas aeruginosa (ATCC 9027, MRI PS 10, and Salmonella Choleraesuis (ATCC 13312, MRI SC 1 or other selected SC) prepared and suspended in Mueller Hinton Broth (MHB) to about 0.5 McFarland turbidity standard.
- microorganisms such as Staphylococcus aureus (ATCC 6538, MRI Sta 21), Pseudomonas aeruginosa (ATCC 9027, MRI PS 10, and Salmonella Choleraesuis (ATCC 13312, MRI SC 1 or other selected SC) prepared and suspended in Mueller Hinton Broth (MHB) to about 0.5
- These bacteria cultures can be diluted to obtain concentrations of about 10 7 through about 10 3 CFU/ml and 10 ⁇ l of each dilution can be spread onto a glass coverslip with a sterile loop and allowed to dry. Afterwards, the coverslips containing 10 5 to 10 2 CFU can be placed inside of petri dish. Different concentrations of the amount of substance can be applied to the cover slips with a nebulizer as described by Germicidal Spray Products as Disinfectants, Method 961.02, AOAC International (2004).
- IPA isopropyl alcohol
- DAA diacetone alcohol
- IPA and DAA can be assessed as above described by obtaining aqueous mixtures of IPA at concentrations of 55% w/w, 20% w/w, and 5% w/w.
- DAA can be assessed by providing concentrations of 60% w/w, 10% w/w, and 6% w/w in water.
- An amount of each concentration of IPA and DAA can be applied to a corresponding cover slip and evaporated to dryness.
- a nutrient agar lightly pressed against the coverslips allows contact of microorganisms on the coverslips with the nutrient agar.
- the nutrient agar can be incubated for 48 hours at 37 ° C in contact with the coverslips and then observed for microbial reproduction in the region where the coverslips contact the nutrient agar.
- Untreated coverslips can be used as a positive control. Particular examples of utilizing the method are set forth below.
- An additional ninth selection step (13) can include a determination as to whether the differential evaporation potentiated antimicrobial composition (12) identified in step 8
- differential evaporation potentiated compositions 10
- the differential evaporation potentiated compositions (10) identified are not intended to be limiting with respect to use of the method to identify additional differential evaporation potentiated compositions (10) or limiting with respect to the scope of differential evaporation potentiated compositions (10) and differential evaporation potentiated antimicrobial compositions (12) encompassed by the invention.
- differential evaporation potentiated compositions (10) can include an alpha hydroxyketone selected from the group consisting of: 3-hydroxy-2-butanone, 3-hydroxy-2-pentanone, 2-hydroxy-3-pentanone, 3-hydroxy-3- methyl-2-pentanone, 3 -hydroxy-4-methyl-2-pentanone, 4-hydroxy-2-methyl-3 -pentanone, 3-hydroxy-2-hexanone, 4-hydroxy-3-hexanone, 4-hydroxy-4-methyl-3-hexanone, 4- hydroxy-5-methyl-3-hexanone, 4-hydroxy-3-heptanone, 4-hydroxy-5-octanone.
- alpha hydroxyketone selected from the group consisting of: 3-hydroxy-2-butanone, 3-hydroxy-2-pentanone, 2-hydroxy-3-pentanone, 3-hydroxy-3- methyl-2-pentanone, 3 -hydroxy-4-methyl-2-pentanone, 4-hydroxy-2-methyl-3 -pentanone, 3-hydroxy-2-hexanone, 4-hydroxy-3-he
- An alpha hydroxyketone can provide an antimicrobially active agent (20) soluble in an inactive agent (21) such as water within a temperature range of between about 5 0 C and about 90°C at about 760mm Hg, and having a boiling point greater than said inactive agent (21) of between about 10°C and about 90°C which allows the inactive agent (21) to evaporate from a mixture of the inactive agent (21) and the alpha hydroxyketone at a greater rate than the alpha hydroxyketone within the temperature range of between about 5°C and about 90 0 C at about 760mm Hg, to provide a differential evaporation potentiated antimicrobial composition (12) which can provide greater than a 2-logio order reduction in a population of viable microorganisms (19).
- differential evaporation potentiated compositions (10) can include a beta hydroxyketone selected from the group consisting of: 4-hydroxy-2-butanone, 4-hydroxy-2-pentanone, l-hydroxy-3 -pentanone, 4-hydroxy-4- methyl-2-pentanone (DAA), 4-hydroxy-2-hexanone, 5-hydroxy-4-methyl-3-hexanone, 5- hydroxy-5-methyl-3 -hexanone, 5 -hydroxy-3 -heptanone, 5 -hydroxy-5 -methyl-3 - heptanone, 3 -hydroxy-3 -methyl-5 -heptanone, 4-hydroxy-3,4-dimethyl-2-hexanone.
- a beta hydroxyketone selected from the group consisting of: 4-hydroxy-2-butanone, 4-hydroxy-2-pentanone, l-hydroxy-3 -pentanone, 4-hydroxy-4- methyl-2-pentanone (DAA), 4-hydroxy-2-hexanone, 5-hydroxy-4-methyl-3-hexanone,
- a beta hydroxyketone can provide an antimicrobially active agent (20) soluble in an inactive agent (21) such as water within a temperature range of between about 5 0 C and about 9O 0 C at about 760mm Hg, and having a boiling point greater than said inactive agent (21) of between about 10°C and about 90 0 C which allows the inactive agent (21) to evaporate from a mixture of the inactive agent (21) and the beta hydroxyketone at a greater rate than the beta hydroxyketone within the temperature range of between about 5°C and about 9O 0 C at about 760mm Hg, to provide a differential evaporation potentiated antimicrobial composition (12) which can provide greater than a 2-logio order reduction in a population of viable microorganisms (19).
- an amount of 4- hydroxy-4-methyl-2-pentanone (also referred to as "diacetone alcohol” or "DAA”) can be combined with water to provide between about 10 % and about 95% 4-hydroxy-4-methyl-
- DAA diacetone alcohol
- inventive differential evaporation potentiated antimicrobial composition (12) including DAA at various concentrations in water were tested as above-described and compared to various concentrations of IPA in water tested as above-described.
- IPA at concentrations of 6% and 25% in water did not reduce the population of viable microorganisms.
- IPA and DAA at concentrations at which the IPA and the DAA evaporated from the mixture at a greater rate than the water performed similarly to reduce populations of microorganisms to less than 50% of the number of colonies counted in the corresponding positive control plate.
- DAA at concentrations at which water evaporated at a greater rate than DAA from the mixture provided greater reduction of populations of microorganisms than 70% IPA (v/v) and provided greater reduction of populations of microorganisms than concentrations of DAA which evaporated from the mixture at a greater rate than the water.
- XXX denotes a plate in which zero colonies were present, representing complete reduction of the number of microorganisms (> 5 Logio reduction).
- XXx denotes a plate where the numbers of colonies represented less than 1% of the number of colonies counted in the corresponding positive control plate, representing nearly complete reduction of the number of microorganisms (> 4 Logio reduction).
- XX denotes a plate where the numbers of colonies represented less than 10% of the number of colonies counted in the corresponding positive control plate, representing a significant reduction of the number of microorganisms (> 3 Logio reduction).
- X denotes a plate where the numbers of colonies represented less than 50% of the number of colonies counted in the corresponding positive control plate, representing reduction of the number of microorganisms ( ⁇ 2 Logio reduction).
- — 0 — denotes a plate where the numbers of colonies represented more than 50% of the number of colonies counted in the corresponding positive control plate, representing no significant reduction in the population of viable microorganisms (0 to 1 Logio reduction ).
- DAA at concentrations of between about 3% and 15% in water (v/v) were comparatively tested for antimicrobial efficacy in a non-evaporative procedure and an evaporative procedure to provide a non- limiting example of evaporative potentiation of DAA.
- the non-evaporative and evaporative procedures included 50 ⁇ L of an overnight Staphylococcus aureus (ATCC 6538, ⁇ 10 9 CFU/mL) culture added to each 2 mL sterile plastic vial with a conical bottom and dried without capping in a centrifuge for 30 minutes.
- XXX denotes a plate in which zero colonies were present, representing complete reduction of the number of microorganisms (> 5 Logio reduction).
- XXx denotes a plate where the numbers of colonies represented less than 1 % of the number of colonies counted in the corresponding positive control plate, representing nearly complete reduction of the number of microorganisms (> 4 Logio reduction).
- XX denotes a plate where the numbers of colonies represented less than 10% of the number of colonies counted in the corresponding positive control plate, representing a significant reduction of the number of microorganisms (> 3 Logio reduction).
- X denotes a plate where the numbers of colonies represented less than 50% of the number of colonies counted in the corresponding positive control plate, representing reduction of the number of microorganisms ( ⁇ 2 Logio reduction).
- — 0 — denotes a plate where the numbers of colonies represented more than 50% of the number of colonies counted in the corresponding positive control plate, representing no significant reduction in the population of viable microorganisms (0 to 1 Logio reduction).
- differential evaporation potentiated compositions (10) can include an ethylene glycol monoether selected from the group consisting of: ethylene glycol monoethyl ether, ethylene glycol monopropyl ether, ethylene glycol monobutyl ether (EGMBE), ethylene glycol monopentyl ether, and ethylene glycol monohexyl ether.
- an ethylene glycol monoether selected from the group consisting of: ethylene glycol monoethyl ether, ethylene glycol monopropyl ether, ethylene glycol monobutyl ether (EGMBE), ethylene glycol monopentyl ether, and ethylene glycol monohexyl ether.
- An ethylene glycol monoether can provide an antimicrobially active agent (20) soluble in an inactive agent (21) such as water within a temperature range of between about 5°C and about 90 0 C at about 760mm Hg, and having a boiling point greater than the inactive agent (20) of between about 10°C and about 90°C which allows the inactive agent (20) to evaporate from a mixture of the inactive agent (20) and the ethylene glycol monoether at a greater rate than the ethylene glycol monoether within the temperature range of between about 5°C and about 90 0 C at about 760mm Hg, to provide a differential evaporation potentiated antimicrobial composition (12) which can provide greater than a
- EGMBE at concentrations of between about between about 15 % and about 95% in water (v/v) and more preferably between about 15 % and about 30 % in water (v/v) were comparatively tested for antimicrobial efficacy in a non-evaporative procedure and an evaporative procedure to provide a non-limiting example of evaporative potentiation of EGMBE by the Potentiation Assay above-described.
- differential evaporation potentiated compositions (10) can include an ethylene glycol diether selected from the group consisting of: ethylene glycol dimethyl ether, ethylene glycol diethyl ether, and ethylene glycol dipropyl ether.
- the ethylene glycol diether can provide an antimicrobially active agent (20) soluble in an inactive agent (21) such as water within a temperature range of between about 5°C and about 90 0 C at about 760mm Hg, and having a boiling point greater than the inactive agent (21) of between about 10°C and about 90°C which allows the inactive agent (21) to evaporate from a mixture of the inactive agent (21) and the ethylene glycol diether at a greater rate than the ethylene glycol diether within the temperature range of between about 5°C and about 90 0 C at about 760mm Hg, to provide a differential evaporation potentiated antimicrobial composition (12) which can provide greater than a 2-logio order reduction in a population of viable microorganisms (19).
- an inactive agent (21) such as water within a temperature range of between about 5°C and about 90 0 C at about 760mm Hg
- an inactive agent (21) such as water within a temperature range of between about 5°C and about 90 0 C
- differential evaporation potentiated compositions (10) can include an ethylene glycol ether ester selected from the group consisting of: ethylene glycol monomethyl ether acetate (EGMEA), ethylene glycol monoethyl ether acetate, ethylene glycol monomethyl ether butyrate, and ethylene glycol monoethyl ether butyrate.
- ethylene glycol ether ester selected from the group consisting of: ethylene glycol monomethyl ether acetate (EGMEA), ethylene glycol monoethyl ether acetate, ethylene glycol monomethyl ether butyrate, and ethylene glycol monoethyl ether butyrate.
- EGMEA at concentrations of between about between about 15 % and about 95% in water
- differential evaporation potentiated compositions (10) can include a propylene glycol monoether selected from the group consisting of: propylene glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol monopropyl ether, propylene glycol monobutyl ether, and propylene glycol monopentyl ether.
- a propylene glycol monoether selected from the group consisting of: propylene glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol monopropyl ether, propylene glycol monobutyl ether, and propylene glycol monopentyl ether.
- differential evaporation potentiated compositions (10) can include a propylene glycol diether selected from the group consisting of: propylene glycol dimethyl ether, and propylene glycol diethyl ether.
- differential evaporation potentiated compositions (10) can include a propylene glycol ether ester selected from the group consisting of: propylene glycol monomethyl ether acetate, propylene glycol monoethyl ether acetate, propylene glycol monomethyl ether butyrate.
- differential evaporation potentiated compositions (10) can include a butylene glycol monoether selected from the group consisting of: butylene glycol monomethyl ether, butylene glycol monoethyl ether, butylene glycol monopropyl ether, and butylene glycol monobutyl ether.
- differential evaporation potentiated compositions (10) can include a butylene glycol diether selected from the group consisting of: butylene glycol dimethyl ether, and butylene glycol diethyl ether.
- differential evaporation potentiated compositions (10) can include a butylene glycol monoether ester selected from the group consisting of: butylene glycol monomethyl ether formate ester, and butylene glycol monoethyl ether acetate.
- differential evaporation potentiated compositions (10) can include an ethylene glycol monoester selected from the group consisting of: ethylene glycol monoethyl ester, ethylene glycol monopropyl ester, ethylene glycol monobutyl ester, ethylene glycol monopentyl ester, and ethylene glycol monohexyl ester.
- an ethylene glycol monoester selected from the group consisting of: ethylene glycol monoethyl ester, ethylene glycol monopropyl ester, ethylene glycol monobutyl ester, ethylene glycol monopentyl ester, and ethylene glycol monohexyl ester.
- compositions (10) shown in Figures 9-15 including a propylene glycol monoether, a propylene glycol diether, a propylene glycol ether ester, a butylene glycol monoether, a propylene glycol diether, a butylene glycol monoether ester, or an ethylene glycol monoester, each can provide an antimicrobially active agent (20) soluble in an inactive agent such as water within a temperature range of between about 5°C and about 90°C at about 760mm Hg, and having a boiling point greater than the inactive agent of between about 10°C and about 9O 0 C which allows the inactive agent (21) to evaporate from a mixture of the inactive agent (21) and the propylene glycol monoether, propylene glycol diether, propylene glycol ether ester, butylene glycol monoether, propylene glycol diether, butylene glycol monoether ester, or ethylene glycol monoester, at a
- differential evaporation potentiated compositions (10) can include an ethylene glycol diester selected from the group consisting of: ethylene glycol dimethyl ester, ethylene glycol diethyl ester (EGDA) and ethylene glycol dipropyl ester.
- ethylene glycol diester selected from the group consisting of: ethylene glycol dimethyl ester, ethylene glycol diethyl ester (EGDA) and ethylene glycol dipropyl ester.
- EGDA at concentrations of between about between about 15 % and about 95% in water (v/v) and more preferably between about 10 % and about 30 % in water (v/v) were comparatively tested for antimicrobial efficacy in a non-evaporative procedure and an evaporative procedure to provide a non-limiting example of evaporative potentiation of EGDA by the Potentiation Assay above-described.
- differential evaporation potentiated compositions (10) can include a propylene glycol monoester selected from the group consisting of: propylene glycol monomethyl ester, propylene glycol monoethyl ester, propylene glycol monopropyl ester, propylene glycol monobutyl ester, and propylene glycol monopentyl ester.
- a propylene glycol monoester selected from the group consisting of: propylene glycol monomethyl ester, propylene glycol monoethyl ester, propylene glycol monopropyl ester, propylene glycol monobutyl ester, and propylene glycol monopentyl ester.
- differential evaporation potentiated compositions (10) can include a propylene glycol diester selected from the group consisting of: propylene glycol dimethyl ester, propylene glycol diethyl ester, propylene glycol dipropyl ester, propylene glycol dibutyl ester, and propylene glycol dipentyl ester.
- differential evaporation potentiated compositions (10) can include a butylene glycol diester selected from the group consisting of: butylene glycol dimethyl ester, butylene glycol diethyl ester, butylene glycol dipropyl ester, or butylene propylene glycol dibutyl ester.
- differential evaporation potentiated compositions (10) can include a butylene glycol ester selected from the group consisting of: butylene glycol methyl ester, or butylene glycol ethyl ester.
- the glycol ester, the propylene glycol monoester, the propylene glycol diester, the butylene glycol diester, the butylene glycol ester selected from the group can provide an antimicrobially active agent (20) soluble in an inactive agent (21 ) such as water within a temperature range of between about 5°C and about 90°C at about 760mm Hg, and having a boiling point greater than the inactive agent of between about 10°C and about 90 0 C which allows the inactive agent (21) to evaporate from a mixture of the inactive agent (21) and the glycol ester, the propylene glycol monoester, the propylene glycol diester, the butylene glycol diester, or the butylene glycol ester at a greater rate than the corresponding one of the antimicrobially active agents (20) within the temperature range of between about 5°C and about 9O 0 C at about 760mm Hg, to provide a differential evaporation potentiated antimicrobial composition (12) which can provide greater than
- differential evaporation potentiated compositions (10) can include an oxime selected from the group consisting of: 2- butanone oxime (MEKO), acetone oxime, methylethylketone oxime (MEKO), 2- pentanone oxime, 3-pentanone oxime, cyclopentanone oxime, 2-hexanone oxime, 3- hexanone oxime and cyclohexanone oxime.
- MEKO at concentrations of between about between about 15 % and about 95% in water (v/v) and more preferably between about 10 % and about 30 % in water (v/v) were comparatively tested for antimicrobial efficacy in a non-evaporative procedure and an evaporative procedure to provide a non-limiting example of evaporative potentiation of EGDA by the Potentiation Assay above-described.
- differential evaporation potentiated compositions (10) can include a dimethylaminoalcohol selected from the group consisting of: 2-dimethylaminoethanol (DMEA), 2-dimethylamino-l-propanol, l-dimethylamino-2- propanol, l-dimethylamino-2-butanol and 3-dimethylamino-2-butanol.
- DMEA 2-dimethylaminoethanol
- 2-dimethylamino-l-propanol 2-dimethylamino-2-propanol
- l-dimethylamino-2- propanol l-dimethylamino-2-butanol
- 3-dimethylamino-2-butanol 3-dimethylamino-2-butanol.
- DMEA at concentrations of between about between about 15 % and about 95% in water (v/v) and more preferably between about 10 % and about 30 % in water (v/v) were comparatively tested for antimicrobial efficacy in a non-evaporative procedure and an evaporative procedure to provide a non-limiting example of evaporative potentiation of DMEA by the Potentiation Assay above-described.
- differential evaporation potentiated compositions (10) can include a pyridine selected from the group consisting of: pyridine, 2-methylpyradine, 3-methylpyradine, 4-methylpyradine.
- the pyridine selected from the group can provide an antimicrobially active agent (20) soluble in an inactive agent (21) such as water within a temperature range of between about 5°C and about 90°C at about 760mm Hg, and having a boiling point greater than the inactive agent (21) of between about 10°C and about 9O 0 C which allows the inactive agent (21) to evaporate from a mixture of the inactive agent (21) and the pyridine at a greater rate than the pyridine within the temperature range of between about 5°C and about 90°C at about 760mm Hg, to provide a differential evaporation potentiated antimicrobial composition (12) which can provide greater than a 2-logio order reduction in a population of viable microorganisms (19).
- an inactive agent (21) such as water within a temperature range of between about 5°C and about 90°C at about 760mm Hg
- a boiling point greater than the inactive agent (21) of between about 10°C and about 9O 0 C which allows the inactive agent (2
- differential evaporation potentiated compositions (10) can include an aliphatic alcohol selected from the group consisting of: 1-butanol and 2-butanol.
- the aliphatic alcohol selected from the group can provide an antimicrobially active agent (20) soluble in an inactive agent (21) such as water within a temperature range of between about 5 0 C and about 90°C at about 760mm Hg, and having a boiling point greater than the inactive agent (21) of between about 1O 0 C and about 90 0 C which allows the inactive agent (21) to evaporate from a mixture of the inactive agent (21) and the butanol at a greater rate than the butanol within the temperature range of between about 5 0 C and about 90 0 C at about 760mm Hg, to provide a differential evaporation potentiated antimicrobial composition (12) which can provide greater than a 2-logio order reduction in a population of viable microorganisms (19).
- an inactive agent (21) such as water within a temperature range of between about 5 0 C and about 90°C at about 760mm Hg, and having a boiling point greater than the inactive agent (21) of between about 1O 0 C and about
- the basic concepts of the present invention may be embodied in a variety of ways.
- the invention involves numerous and varied embodiments of a differential evaporation potentiated disinfectant system and methods of making and using such differential evaporation potentiated disinfectant system.
- each element of an apparatus or each step of a method may be described by an apparatus term or method term. Such terms can be substituted where desired to make explicit the implicitly broad coverage to which this invention is entitled. As but one example, it should be understood that all steps of a method may be disclosed as an action, a means for taking that action, or as an element which causes that action. Similarly, each element of an apparatus may be disclosed as the physical element or the action which that physical element facilitates.
- the disclosure of a "disinfectant” should be understood to encompass disclosure of the act of "disinfecting” — whether explicitly discussed or not — and, conversely, were there effectively disclosure of the act of "disinfecting", such a disclosure should be understood to encompass disclosure of a “disinfectant” and even a “means for disinfecting.”
- Such alternative terms for each element or step are to be understood to be explicitly included in the description.
- each of the differential evaporation potentiated compositions and differential evaporation potentiated antimicrobial compositions herein disclosed and described ii) the related methods disclosed and described, iii) similar, equivalent, and even implicit variations of each of these devices and methods, iv) those alternative embodiments which accomplish each of the functions shown, disclosed, or described, v) those alternative designs and methods which accomplish each of the functions shown as are implicit to accomplish that which is disclosed and described, vi) each feature, component, and step shown as separate and independent inventions, vii) the applications enhanced by the various systems or components disclosed, viii) the resulting products produced by such systems or components, ix) methods and apparatuses substantially as described hereinbefore and with reference to any of the accompanying examples, x) the various combinations and permutations of each of the previous elements disclosed.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010525810A JP2010539233A (en) | 2007-09-19 | 2008-09-12 | Disinfectant system enhanced by differential evaporation |
US12/733,709 US20100249166A1 (en) | 2007-09-19 | 2008-09-12 | Differential evaporation potentiated disinfectant system |
EP08832486.8A EP2209381B1 (en) | 2007-09-19 | 2008-09-12 | Differential evaporation potentiated disinfectant system |
CA2700068A CA2700068C (en) | 2007-09-19 | 2008-09-12 | Differential evaporation potentiated disinfectant system |
BRPI0817127A BRPI0817127A2 (en) | 2007-09-19 | 2008-09-12 | potentiated differential evaporation disinfectant system |
US13/952,536 US9474814B2 (en) | 2007-09-19 | 2013-07-26 | Differential evaporation potentiated disinfectant system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/901,915 | 2007-09-19 | ||
US11/901,915 US8119688B2 (en) | 2007-09-19 | 2007-09-19 | Differential evaporation potentiated disinfectant system |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/901,915 Continuation-In-Part US8119688B2 (en) | 2007-09-19 | 2007-09-19 | Differential evaporation potentiated disinfectant system |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/733,709 A-371-Of-International US20100249166A1 (en) | 2007-09-19 | 2008-09-12 | Differential evaporation potentiated disinfectant system |
US13/952,536 Continuation US9474814B2 (en) | 2007-09-19 | 2013-07-26 | Differential evaporation potentiated disinfectant system |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009038672A1 true WO2009038672A1 (en) | 2009-03-26 |
Family
ID=40455270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/010684 WO2009038672A1 (en) | 2007-09-19 | 2008-09-12 | Differential evaporation potentiated disinfectant system |
Country Status (6)
Country | Link |
---|---|
US (1) | US8119688B2 (en) |
EP (1) | EP2209381B1 (en) |
JP (1) | JP2010539233A (en) |
BR (1) | BRPI0817127A2 (en) |
CA (1) | CA2700068C (en) |
WO (1) | WO2009038672A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101243240B1 (en) * | 2010-07-19 | 2013-04-04 | (주)에이씨티 | Novel derivatives of alkyldiol compound and whitening composition for external skin comprising the same |
US8846767B2 (en) | 2005-04-07 | 2014-09-30 | Cdh Bioscience, Inc. | Flow path conditioner system |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100249166A1 (en) | 2007-09-19 | 2010-09-30 | Xy, Inc. | Differential evaporation potentiated disinfectant system |
GB201322840D0 (en) * | 2013-12-23 | 2014-02-12 | Imerys Minerals Ltd | Aqueous suspension of inorganic particulate material |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248343B1 (en) * | 1998-01-20 | 2001-06-19 | Ethicon, Inc. | Therapeutic antimicrobial compositions |
US20030113673A1 (en) * | 2001-12-14 | 2003-06-19 | Seung-Hyun Ahn | Photoresist stripper compositions |
US20040246321A1 (en) * | 2003-03-19 | 2004-12-09 | Fuji Photo Film Co., Ltd. | Ink-jet recording method |
US20050003020A1 (en) * | 2002-11-04 | 2005-01-06 | Smith Jeffrey B. | Anti-viral compositions and methods of making and using the anti-viral compositions |
US20050031994A1 (en) * | 2003-08-06 | 2005-02-10 | Toshio Banba | Polyamide resin, positive-working photosensitive resin composition, method for producing pattern-formed resin film, semiconductor device, display device, and method for producing the semiconductor device and the display device |
US20050080194A1 (en) * | 2001-11-20 | 2005-04-14 | San-Dia Polymers, Ltd. | Water absorbing agent, process for its production, and absorbers and absorbent articles made by using the agent |
US20050209223A1 (en) * | 2002-01-18 | 2005-09-22 | Dr. Reddy's Laboratories Limited | Novel antibacterial compounds: process for their preparation and pharmaceutical compositions containing them |
US20060160712A1 (en) * | 2000-04-28 | 2006-07-20 | Hei Robert D | Antimicrobial composition |
US20060229367A1 (en) | 2005-04-07 | 2006-10-12 | Xy, Inc. | Flow path conditioner system |
US20060257436A1 (en) * | 2003-04-04 | 2006-11-16 | Shiseido Company, Ltd. | Skin preparation composition for external use |
US20060263399A1 (en) * | 2005-05-20 | 2006-11-23 | Rikako Yasuno | Preparation for external use on skin |
US20060293214A1 (en) * | 2005-06-28 | 2006-12-28 | Lily Cheng | Synergistic acidic ternary biocidal compositions |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1654103A (en) * | 1925-03-19 | 1927-12-27 | Du Pont | Method of condensation |
US3226211A (en) * | 1962-05-29 | 1965-12-28 | Gulf Research Development Co | Inhibiting growth of microorganisms in fuel compositions |
US3756459A (en) * | 1971-01-12 | 1973-09-04 | Damon Corp | Method and apparatus for metering fluid utilizing pressure differentials |
US4201764A (en) * | 1973-01-15 | 1980-05-06 | Calvin N. Goeders | Spray disinfectant aerosol |
FR2588264B1 (en) * | 1985-10-07 | 1987-11-27 | Sterling Sa Division Phagogene | DISINFECTANT COMPOSITION FOR AIRWAY |
US4796788A (en) * | 1987-08-26 | 1989-01-10 | Liqui-Box Corporation | Bag-in-box packaging and dispensing of substances which will not readily flow by gravity |
JPH02188504A (en) * | 1989-01-17 | 1990-07-24 | Osaka Kasei Kk | Self-adsorbable antimicrobial agent and fiber product treated with the same antimicrobial agent |
US5492534A (en) * | 1990-04-02 | 1996-02-20 | Pharmetrix Corporation | Controlled release portable pump |
US5559032A (en) * | 1990-06-29 | 1996-09-24 | Pomeroy; Patrick C. | Method and apparatus for post-transfer assaying of material on solid support |
DE4124246A1 (en) * | 1991-07-22 | 1993-01-28 | Henkel Kgaa | CLEANING AGENT FOR ELECTRONIC AND ELECTRICAL ASSEMBLIES |
CA2140141A1 (en) * | 1992-07-13 | 1994-01-20 | Eric J. Krasnoff | Automated system and method for processing biological fluid |
US6328071B1 (en) * | 1993-08-06 | 2001-12-11 | Cary Austin | Well pressure tank |
FR2723735B1 (en) * | 1994-08-18 | 1996-10-31 | Abx Sa | AUTOMATIC CONNECTION BOX FOR DISPENSING REAGENTS IN AN APPARATUS IN PARTICULAR A HEMATOLOGICAL ANALYZER. |
FR2729137A1 (en) * | 1995-01-06 | 1996-07-12 | Atochem Elf Sa | SELECTIVE ALDOLIZATION OF ACETONE IN DIACETONEALCOOL BY A SOLID BASIC CATALYST |
JP3875754B2 (en) * | 1995-11-17 | 2007-01-31 | シスメックス株式会社 | Standard solution for flow cytometer |
BR9600722A (en) * | 1996-02-14 | 1997-12-30 | Jorge Antonio Rodrigues Claro | Infusion pump for contained in flexible plastic bags |
EP1012450B1 (en) * | 1996-08-07 | 2004-10-20 | Cuno Incorporated | Additive dispensing apparatus |
US5799830A (en) * | 1996-11-08 | 1998-09-01 | Carroll; David C. | Pressure vessel access port |
JP2978815B2 (en) * | 1997-03-25 | 1999-11-15 | 静岡日本電気株式会社 | Radio selective call receiver |
US6086574A (en) * | 1997-11-21 | 2000-07-11 | Hyclone Laboratories, Inc. | Fluid delivery systems with diptube connector |
US6251615B1 (en) * | 1998-02-20 | 2001-06-26 | Cell Analytics, Inc. | Cell analysis methods |
CH689805A8 (en) * | 1998-07-02 | 2000-02-29 | Smithkline Beecham Plc | Paroxetine methanesulfonate, process for its preparation and pharmaceutical compositions containing it. |
US6729369B2 (en) * | 1998-07-31 | 2004-05-04 | Chata Biosystems, Inc. | Vessel for containing/transporting a fluent substance |
US20040107150A1 (en) * | 1998-07-31 | 2004-06-03 | Chata Biosystems, Inc. Of Colorado | Apparatus and method with vessel for containing/transporting a fluent substance |
YU7701A (en) * | 1998-08-04 | 2003-01-31 | Dipro Diagnostics Handels Gmbh. | Method for detecting drugs, and a solvent and a decomposition solution therefor |
FR2791645B1 (en) * | 1999-04-02 | 2001-06-15 | Valois Sa | FLUID PRODUCT SAMPLE FOR PRESS |
US6793387B1 (en) * | 1999-05-08 | 2004-09-21 | Chata Biosystems, Inc. | Apparatus for automatic preparation of a mixture and method |
FR2793708B1 (en) * | 1999-05-21 | 2001-08-03 | Valois Sa | FLUID PRODUCT DISPENSING DEVICE |
FR2795088B1 (en) * | 1999-06-21 | 2002-05-24 | Atofina | COLD CLEANING COMPOSITIONS OF THE MICROEMULSION TYPE |
US6495366B1 (en) * | 1999-09-03 | 2002-12-17 | Therakos, Inc. | Uninterrupted flow pump apparatus and method |
US6593283B2 (en) * | 2000-04-28 | 2003-07-15 | Ecolab Inc. | Antimicrobial composition |
US7271137B2 (en) * | 2000-06-29 | 2007-09-18 | Sandia Corporation | Decontamination formulations for disinfection and sterilization |
AUPQ893200A0 (en) * | 2000-07-21 | 2000-08-17 | Whiteley, Reginald K. | Medical residue treatment |
FR2813283B1 (en) * | 2000-08-25 | 2003-02-14 | Valois Sa | INTEGRATED PUMP DISPENSER |
JP2002161001A (en) * | 2000-09-12 | 2002-06-04 | Iwao Hishida | Disinfectant |
SG160186A1 (en) * | 2000-10-23 | 2010-04-29 | Medical Instill Tech Inc | Fluid dispenser having a rigid vial and flexible inner bladder |
US6699825B2 (en) * | 2001-01-12 | 2004-03-02 | S.C. Johnson & Son, Inc. | Acidic hard-surface antimicrobial cleaner |
GB0104153D0 (en) * | 2001-02-20 | 2001-04-11 | Reckitt Benckiser Inc | Improvements in or relating to organic compositions |
FR2825987B1 (en) * | 2001-06-19 | 2003-12-12 | Valois Sa | FLUID PRODUCT DISPENSER |
US20030095897A1 (en) * | 2001-08-31 | 2003-05-22 | Grate Jay W. | Flow-controlled magnetic particle manipulation |
US6698627B2 (en) * | 2002-02-19 | 2004-03-02 | Valois S.A.S. | Fluid dispenser |
JP2004154679A (en) * | 2002-11-06 | 2004-06-03 | Junichi Iwamura | Washing and sterilizing equipment |
WO2004080179A1 (en) * | 2003-03-10 | 2004-09-23 | Xantech Pharmaceuticals, Inc. | Surface sanitizing compositions with improved antimicrobial performance |
US20050011582A1 (en) * | 2003-06-06 | 2005-01-20 | Haug Jeffrey S. | Fluid delivery system for a flow cytometer |
CN1867251A (en) * | 2003-09-09 | 2006-11-22 | 3M创新有限公司 | Antimicrobial compositions and methods |
US20060118167A1 (en) | 2004-12-03 | 2006-06-08 | Xy, Inc. | Pressure regulated continuously variable volume container for fluid delivery |
JP4834307B2 (en) * | 2005-01-14 | 2011-12-14 | 横浜油脂工業株式会社 | Disinfecting and cleaning composition comprising peracetic acid and a nonionic surfactant |
US20070053866A1 (en) * | 2005-09-06 | 2007-03-08 | Novus International Inc. | In-can and dry coating antimicrobial compositions having hydroxy analogs of methionine and derivatives |
-
2007
- 2007-09-19 US US11/901,915 patent/US8119688B2/en active Active
-
2008
- 2008-09-12 JP JP2010525810A patent/JP2010539233A/en active Pending
- 2008-09-12 CA CA2700068A patent/CA2700068C/en not_active Expired - Fee Related
- 2008-09-12 EP EP08832486.8A patent/EP2209381B1/en active Active
- 2008-09-12 BR BRPI0817127A patent/BRPI0817127A2/en not_active Application Discontinuation
- 2008-09-12 WO PCT/US2008/010684 patent/WO2009038672A1/en active Application Filing
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248343B1 (en) * | 1998-01-20 | 2001-06-19 | Ethicon, Inc. | Therapeutic antimicrobial compositions |
US20060160712A1 (en) * | 2000-04-28 | 2006-07-20 | Hei Robert D | Antimicrobial composition |
US20050080194A1 (en) * | 2001-11-20 | 2005-04-14 | San-Dia Polymers, Ltd. | Water absorbing agent, process for its production, and absorbers and absorbent articles made by using the agent |
US20030113673A1 (en) * | 2001-12-14 | 2003-06-19 | Seung-Hyun Ahn | Photoresist stripper compositions |
US20050209223A1 (en) * | 2002-01-18 | 2005-09-22 | Dr. Reddy's Laboratories Limited | Novel antibacterial compounds: process for their preparation and pharmaceutical compositions containing them |
US20050003020A1 (en) * | 2002-11-04 | 2005-01-06 | Smith Jeffrey B. | Anti-viral compositions and methods of making and using the anti-viral compositions |
US20040246321A1 (en) * | 2003-03-19 | 2004-12-09 | Fuji Photo Film Co., Ltd. | Ink-jet recording method |
US20060257436A1 (en) * | 2003-04-04 | 2006-11-16 | Shiseido Company, Ltd. | Skin preparation composition for external use |
US20050031994A1 (en) * | 2003-08-06 | 2005-02-10 | Toshio Banba | Polyamide resin, positive-working photosensitive resin composition, method for producing pattern-formed resin film, semiconductor device, display device, and method for producing the semiconductor device and the display device |
US20060229367A1 (en) | 2005-04-07 | 2006-10-12 | Xy, Inc. | Flow path conditioner system |
US20060263399A1 (en) * | 2005-05-20 | 2006-11-23 | Rikako Yasuno | Preparation for external use on skin |
US20060293214A1 (en) * | 2005-06-28 | 2006-12-28 | Lily Cheng | Synergistic acidic ternary biocidal compositions |
Non-Patent Citations (7)
Title |
---|
"ASTM D7094-04 Standard Test Method for Flash Point by Modified Continuously Closed Cup (MCCCFP) Tester", 2007, ASTM INTERNATIONAL |
"Germicidal Spray Products as Disinfectants, Method 961.02", 2004, AOAC INTERNATIONAL |
"Product Properties Test Guidelines", 1996, UNITED STATES ENVIRONMENTAL PROTECTION AGENCY, article "Boiling Point/Boiling Point Range" |
"Product Properties Test Guidelines", 1996, UNITED STATES ENVIRONMENTAL PROTECTION AGENCY, article "Melting Point/Melting Point Range" |
"Slow-stirred Method for Determining the n-Octanol/Water Partition Coefficient (P ) for Highly Hydrophobic Chemicals: Performance Evaluation in a Ring Test", ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY, vol. 22, no. 5, May 2003 (2003-05-01) |
FURUTA T ET AL., ANTIMICROBIAL ACTIVITY OF WATER-SOLUBLE SOLVENTS |
R PATCH ET AL., DER EINFLUSS VERSCHIEDENER ORGANISCHER LOSUNGSMITTEL AUF DAS WACHSTUM VON BAKTERIEN |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8846767B2 (en) | 2005-04-07 | 2014-09-30 | Cdh Bioscience, Inc. | Flow path conditioner system |
US8877818B2 (en) | 2005-04-07 | 2014-11-04 | Xy, Llc | Antimicrobially active compositions |
US9750244B2 (en) | 2005-04-07 | 2017-09-05 | Xy, Llc | Antimicrobially active compositions |
KR101243240B1 (en) * | 2010-07-19 | 2013-04-04 | (주)에이씨티 | Novel derivatives of alkyldiol compound and whitening composition for external skin comprising the same |
Also Published As
Publication number | Publication date |
---|---|
CA2700068A1 (en) | 2009-03-26 |
EP2209381B1 (en) | 2017-08-30 |
CA2700068C (en) | 2015-11-03 |
JP2010539233A (en) | 2010-12-16 |
EP2209381A1 (en) | 2010-07-28 |
US20090076169A1 (en) | 2009-03-19 |
US8119688B2 (en) | 2012-02-21 |
BRPI0817127A2 (en) | 2019-05-28 |
EP2209381A4 (en) | 2013-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6921745B2 (en) | Bactericidal composition comprising polylysine and a plant essential oil | |
US5405602A (en) | Nonaqueous cold sterilant | |
AU2007235442B2 (en) | High concentration single phase gycol aerosol air sanitizer with dimethyl ether propellant/solvent | |
US20080069780A1 (en) | High Concentration Single Phase Gycol Aerosol Air Sanitizer with Dimethyl Ether Propellant/Solvent | |
US5441723A (en) | Non-toxic hypocompatible biodegradable germicide | |
US8147877B2 (en) | Essential oils based disinfecting compositions having tuberculocidal and fungicidal efficacies | |
JPH05271073A (en) | Anti (pseudomonas aeruginosa) agent | |
US8119688B2 (en) | Differential evaporation potentiated disinfectant system | |
US9474814B2 (en) | Differential evaporation potentiated disinfectant system | |
US5122301A (en) | Antimicrobial compositions containing propylene carbonate and/or ethylene carbonate as the carrier solvent | |
US9456602B2 (en) | Method for the formulation of hand sanitizer | |
JP2010539233A5 (en) | ||
JP2023510638A (en) | Disinfectant composition and system for disinfection | |
Lamba | Antimicrobial activities of aldehydes and ketones produced during rapid volatilization of biogenic oils | |
WO2024026235A1 (en) | Polymer enhanced hydroalcoholic disinfecting composition | |
US20230137655A1 (en) | Antimicrobial compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08832486 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12733709 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010525810 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2700068 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2008832486 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008832486 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: PI0817127 Country of ref document: BR Free format text: 1) ESCLARECA A DIVERGENCIA NO QUADRO DE DEPOSITANTES DO PEDIDO, VISTO QUE O DEPOSITANTE ?CHATA BIOSYSTEMS, INC.? NAO CONSTA NO PEDIDO INTERNACIONAL COMO DEPOSITANTE PARA A FASE NACIONAL BRASILEIRA. SE A DIVERGENCIA SE DEU POR CESSAO DO PEDIDO INTERNACIONAL, APRESENTE O DOCUMENTO DE CESSAO RESPECTIVO, ACOMPANHADO DE SUA TRADUCAO SIMPLES, COM DATA ANTERIOR A ENTRADA DA FASE NACIONAL. 2) CABE SALIENTAR QUE ALTERACAO DE NOME DO DEPOSITANTE ?XY, INC.?, REALIZADA NA PETICAO NO 020110096612 ESTA IRREGULAR, JA QUE O PROCEDIMENTO DE ALTERACAO DE NOME POSSUI GRU E PROCEDIMENTO PROPRIOS. |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01Y Ref document number: PI0817127 Country of ref document: BR Free format text: ANULADA A PUBLICACAO CODIGO 1.5 NA RPI NO 2511 DE 19/02/2019 POR TER SIDO INDEVIDA. |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: PI0817127 Country of ref document: BR Free format text: ESCLARECA A DIVERGENCIA NO QUADRO DE DEPOSITANTES DO PEDIDO, VISTO QUE O DEPOSITANTE ?CHATA BIOSYSTEMS, INC.? NAO CONSTA NO PEDIDO INTERNACIONAL COMO DEPOSITANTE PARA A FASE NACIONAL BRASILEIRA, SOMENTE PARA OS ESTADOS UNIDOS. SE A DIVERGENCIA SE DEU POR CESSAO DO PEDIDO INTERNACIONAL, APRESENTE O DOCUMENTO DE CESSAO RESPECTIVO, ACOMPANHADO DE SUA TRADUCAO SIMPLES, COM DATA ANTERIOR A ENTRADA DA FASE NACIONAL. CASO CONTRARIO, O PEDIDO DEVE SER RETIFICADO PARA QUE CONSTE APENAS O DEPOSITANTE ?XY, INC? COMO DEPOSITANTE ORIGINAL DO PEDIDO E A ALTERACAO DEVE SER REALIZADA POR TRANSFERENCIA QUE POSSUI PROCEDIMENTO, GRU E FORMULARIO PROPRIOS. |
|
ENP | Entry into the national phase |
Ref document number: PI0817127 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100319 |